Clinical Practice and Cases in Emergency Medicine
Empagliflozin-induced Diabetic Ketoacidosis Unmasking a Type 1 Diabetes Diagnosis
- Author(s): Ray, Gretchen M.
- Rodriguez, Chelsea
- Schulman, Samantha
- Sarangarm, Preeyaporn
- Bardack, Michelle
- Bouchonville, Matthew F.
- et al.
Published Web Locationhttps://doi.org/10.5811/cpcem.2019.2.41795
Empagliflozin is a sodium glucose cotransporter-2 inhibitor that inhibits renal glucose reabsorption through an insulin-independent mechanism. This class of drugs is used in the management of type 2 diabetes. A 49-year-old female with type 2 diabetes treated with empagliflozin presented to the emergency department in diabetic ketoacidosis (DKA). This case report details the series of events leading to the diagnosis of drug-induced DKA, which led to a change in the patient’s diagnosis from type 2 diabetes to type 1 diabetes.